DNDN Share Price

Open 0.16 Change Price %
High 0.17 1 Day -0.02 -13.33
Low 0.13 1 Week 0.00 0.00
Close 0.13 1 Month 0.00 0.00
Volume 22710968 1 Year 0.00 0.00
52 Week High 35.15
52 Week Low 0.00
DNDN Important Levels
Resistance 2 0.17
Resistance 1 0.15
Pivot 0.14
Support 1 0.11
Support 2 0.09
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ASTI 0.00 0.00%
SIRI 5.29 3.32%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
NIHD 0.74 39.62%
NIHD 0.74 39.62%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEZS 1.18 22.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
CLSN 0.23 -93.11%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Dendreon Corporation (NASDAQ: DNDN)

DNDN Technical Analysis 5
As on 18th Nov 2014 DNDN Share Price closed @ 0.13 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.20 & Strong Sell for SHORT-TERM with Stoploss of 1.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
DNDN Target for May
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
DNDN Other Details
Segment EQ
Market Capital 648131712.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.dendreon.com
DNDN Address
DNDN
1301 2nd Avenue
Seattle, WA 98101
United States
Phone: 206-256-4545
Fax: 206-256-0571
DNDN Latest News
Interactive Technical Analysis Chart Dendreon Corporation ( DNDN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Dendreon Corporation
DNDN Business Profile
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates the Company has under development include its investigational active cellular immunotherapy, DN24-02. The Company completed its Phase I clinical trial in April 2012 to evaluate Transient Receptor Potential, sub-family M (TRPM8).